Gilead Sciences Inc (GILD)
66.83
-0.20
(-0.30%)
USD |
NASDAQ |
Apr 24, 14:20
Gilead Sciences Revenue (Quarterly): 7.114B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.114B |
| September 30, 2023 | 7.05B |
| June 30, 2023 | 6.599B |
| March 31, 2023 | 6.352B |
| December 31, 2022 | 7.389B |
| September 30, 2022 | 7.042B |
| June 30, 2022 | 6.26B |
| March 31, 2022 | 6.59B |
| December 31, 2021 | 7.244B |
| September 30, 2021 | 7.421B |
| June 30, 2021 | 6.217B |
| March 31, 2021 | 6.423B |
| December 31, 2020 | 7.421B |
| September 30, 2020 | 6.577B |
| June 30, 2020 | 5.143B |
| March 31, 2020 | 5.548B |
| December 31, 2019 | 5.879B |
| September 30, 2019 | 5.604B |
| June 30, 2019 | 5.685B |
| March 31, 2019 | 5.281B |
| December 31, 2018 | 5.795B |
| September 30, 2018 | 5.596B |
| June 30, 2018 | 5.648B |
| March 31, 2018 | 5.088B |
| December 31, 2017 | 5.949B |
| Date | Value |
|---|---|
| September 30, 2017 | 6.512B |
| June 30, 2017 | 7.141B |
| March 31, 2017 | 6.505B |
| December 31, 2016 | 7.32B |
| September 30, 2016 | 7.50B |
| June 30, 2016 | 7.776B |
| March 31, 2016 | 7.794B |
| December 31, 2015 | 8.506B |
| September 30, 2015 | 8.295B |
| June 30, 2015 | 8.244B |
| March 31, 2015 | 7.594B |
| December 31, 2014 | 7.314B |
| September 30, 2014 | 6.042B |
| June 30, 2014 | 6.535B |
| March 31, 2014 | 4.999B |
| December 31, 2013 | 3.120B |
| September 30, 2013 | 2.783B |
| June 30, 2013 | 2.767B |
| March 31, 2013 | 2.532B |
| December 31, 2012 | 2.588B |
| September 30, 2012 | 2.427B |
| June 30, 2012 | 2.405B |
| March 31, 2012 | 2.282B |
| December 31, 2011 | 2.200B |
| September 30, 2011 | 2.122B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.143B
Minimum
Jun 2020
7.421B
Maximum
Dec 2020
6.503B
Average
6.577B
Median
Sep 2020
Revenue (Quarterly) Benchmarks
| Amgen Inc | 8.196B |
| Johnson & Johnson | 21.38B |
| Eli Lilly and Co | 9.353B |
| Pfizer Inc | 14.25B |
| CymaBay Therapeutics Inc (DELISTED) | 0.057M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.429B |
| Total Expenses (Quarterly) | 5.106B |
| EPS Diluted (Quarterly) | 1.14 |
| Enterprise Value | 101.14B |
| Gross Profit Margin (Quarterly) | 70.62% |
| Profit Margin (Quarterly) | 20.09% |
| Earnings Yield | 6.73% |
| Operating Earnings Yield | 10.48% |
| Normalized Earnings Yield | 7.856 |